

- World Health Organization, Research for International Tobacco Control. *WHO Report on the Global Tobacco Epidemic, 2008: the MPOWER Package*. Geneva: World Health Organization; 2008.
- Giovino GA, Mirza SA, Samet JM, et al. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. *Lancet* 2012;380:668–679.
- Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults—United States, 2011. *MMWR Morb Mortal Wkly Rep* 2012;61:889–894.
- Proctor R. *Golden Holocaust: Origins of the Cigarette Catastrophe and the Case for Abolition*. Berkeley: University of California Press; 2011.
- Centers for Disease Control and Prevention (CDC). Consumption of cigarettes and combustible tobacco—United States, 2000–2011. *MMWR Morb Mortal Wkly Rep* 2012;61:565–569.
- Centers for Disease Control and Prevention (CDC). Cigarette use among high school students—United States, 1991–2009. *MMWR Morb Mortal Wkly Rep* 2010;59:797–801.
- Centers for Disease Control and Prevention (CDC). Tobacco use among middle and high school students—United States, 2000–2009. *MMWR Morb Mortal Wkly Rep* 2010;59:1063–1068.
- Centers for Disease Control and Prevention (CDC). Tobacco product use among middle and high school students—United States, 2011 and 2012. *MMWR Morb Mortal Wkly Rep* 2013;62:893–897.
- Cummings KM, Fong GT, Borland R. Environmental influences on tobacco use: evidence from societal and community influences on tobacco use and dependence. *Annu Rev Clin Psychol* 2009;5:433–458.
- Huang J, Chaloupka FJ, Fong GT. Cigarette graphic warning labels and smoking prevalence in Canada: a critical examination and reformulation of the FDA regulatory impact analysis. *Tob Control* 2014;1:17–i12.
- Chaloupka FJ, Yurekli A, Fong GT. Tobacco taxes as a tobacco control strategy. *Tob Control* 2012;21:172–180.
- Centers for Disease Control and Prevention (CDC). State-specific trends in lung cancer incidence and smoking—United States, 1999–2008. *MMWR Morb Mortal Wkly Rep* 2011;60:1243–1247.
- Holford TR, Meza R, Warner KE, et al. Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964–2012. *JAMA* 2014;311:164–171.
- Slama K. The FCTC enters into effect in 2005. *Int J Tuberc Lung Dis* 2005;9:119.
- Liberman J. Four COPs and counting: achievements, underachievements and looming challenges in the early life of the WHO FCTC Conference of the Parties. *Tob Control* 2012;21:215–220.
- Deyton LR. FDA tobacco product regulations: a powerful tool for tobacco control. *Public Health Rep* 2011;126:167–169.
- Patterson JT. *The Dread Disease: Cancer and Modern American Culture*. Cambridge, MA: Harvard University Press; 1987.
- Proctor R. *The Nazi War on Cancer*. Princeton: Princeton University Press; 1999.
- Doll R, Hill AB. Smoking and carcinoma of the lung: a preliminary report. *BMJ* 1950;2:739–748.
- Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma: a study of six hundred and eighty-four proved cases. *JAMA* 1950;143:329–336.
- US Department of Health and Human Services. *The Health Consequences of Smoking: A Report of the Surgeon General*. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
- Centers for Disease Control and Prevention (CDC). Smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 2000–2004. *MMWR Morb Mortal Wkly Rep* 2008;57:1226–1228.
- US Department of Health and Human Services. *The Health Consequences of Smoking—50 Years of Progress. A Report of the Surgeon General*. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
- Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. *N Engl J Med* 2013;368:341–350.
- Gaudet MM, Capstur SM, Sun J, et al. Active smoking and breast cancer risk: original cohort data and meta-analysis. *J Natl Cancer Inst* 2013;105:515–525.
- Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. *BMJ* 2000;321:323–329.
- Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. *N Engl J Med* 2013;368:351–364.
- Burns DM, Anderson CM, Gray N. Has the lung cancer risk from smoking increased over the last fifty years? *Cancer Causes Control* 2011;22:389–397.
- Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. *Clin Pharmacol Ther* 2008;83:531–541.
- Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. *Annu Rev Pharmacol Toxicol* 2009;49:57–71.
- Benowitz NL. Nicotine addiction. *N Engl J Med* 2010;362:2295–2303.
- Scherer G. Smoking behaviour and compensation: a review of the literature. *Psychopharmacology (Berl)* 1999;145:1–20.
- Hammond D, Fong GT, Cummings KM, et al. Smoking topography, brand switching, and nicotine delivery: results from an in vivo study. *Cancer Epidemiol Biomarkers Prev* 2005;14:1370–1375.
- Benowitz NL, Hukkanen J, Jacob P. Nicotine chemistry, metabolism, kinetics and biomarkers. *Handb Exp Pharmacol* 2009;29:60.
- Benowitz NL, Swan GE, Jacob P, et al. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. *Clin Pharmacol Ther* 2006;80:457–467.
- Johnstone E, Benowitz N, Cargill A, et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. *Clin Pharmacol Ther* 2006;80:319–330.
- Malaiyandi V, Lerman C, Benowitz NL, et al. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. *Mol Psychiatry* 2006;11:400–409.
- Lea RA, Dickson S, Benowitz NL. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. *J Anal Toxicol* 2006;30:386–389.
- St Helen G, Novalen M, Heitjan DF, et al. Reproducibility of the nicotine metabolite ratio in cigarette smokers. *Cancer Epidemiol Biomarkers Prev* 2012;21:1105–1114.
- Benowitz NL, Dains KM, Dempsey D, et al. Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure. *Nicotine Tob Res* 2011;13:772–783.
- Dempsey DA, St Helen G, Jacob P, et al. Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and asian nonsmokers. *Clin Pharmacol Ther* 2013;94:687–694.
- Zhu AZ, Renner CC, Hatsukami DK, et al. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. *Cancer Epidemiol Biomarkers Prev* 2013;22:708–718.
- Schnoll RA, Patterson F, Wileyto EP, et al. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. *Pharmacol Biochem Behav* 2009;92:6–11.
- Fong GT, Hammond D, Laux FL, et al. The near-universal experience of regret among smokers in four countries: findings from the International Tobacco Control Policy Evaluation Survey. *Nicotine Tob Res* 2004;6:S341–S351.
- Lee WB, Fong GT, Zanna MP, et al. Regret and rationalization among smokers in Thailand and Malaysia: findings from the International Tobacco Control Southeast Asia Survey. *Health Psychol* 2009;28:457–464.
- Sansone N, Fong GT, Lee WB, et al. Comparing the experience of regret and its predictors among smokers in four Asian countries: findings from the ITC surveys in Thailand, South Korea, Malaysia, and China. *Nicotine Tob Res* 2013;15:1663–1672.
- Tobacco Use and Dependence Guideline Panel. *Treating Tobacco Use and Dependence: 2008 Update*. Rockville, MD: U.S. Department of Health and Human Services; 2008.
- Wynder EL, Hoffmann D. *Tobacco and Tobacco Smoke*. New York: Academic Press; 1967.
- Cummings KM, Morley CP, Hyland A. Failed promises of the cigarette industry and its effect on consumer misperceptions about the health risks of smoking. *Tob Control* 2002;11:1110–1117.
- Pollay RW, Dewhirst T. The dark side of marketing seemingly “Light” cigarettes: successful images and failed fact. *Tob Control* 2002;11:118–131.
- Fairchild A, Colgrove J. Out of the ashes: the life, death, and rebirth of the “safer” cigarette in the United States. *Am J Public Health* 2004;94:192–204.
- Hoffmann D, Hoffmann I. The changing cigarette, 1950–1995. *J Toxicol Environ Health*. 1997;50:307–364.
- Jarvis MJ. Trends in sales weighted tar, nicotine, and carbon monoxide yields of UK cigarettes. *Thorax* 2001;56:960–963.
- O’Connor RJ, Cummings KM, Giovino GA, et al. How did UK cigarette makers reduce tar to 10 mg or less? *BMJ*. 2006;332:302.
- National Cancer Institute. *Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine*. Bethesda, MD: The Institute; 2001.
- Harris JE, Thun MJ, Mondul AM, et al. Cigarette tar yields in relation to mortality from lung cancer in the cancer prevention study II prospective cohort, 1982–8. *BMJ* 2004;328:72.
- Thun MJ, Burns DM. Health impact of “reduced yield” cigarettes: a critical assessment of the epidemiological evidence. *Tob Control* 2001;10:4–11.
- Benowitz NL, Jacob P, Bernert JT, et al. Carcinogen exposure during short-term switching from regular to “light” cigarettes. *Cancer Epidemiol Biomarkers Prev* 2005;14:1376–1383.
- Burns DM, Anderson CM, Gray N. Do changes in cigarette design influence the rise in adenocarcinoma of the lung? *Cancer Causes Control* 2011;22:13–22.

60. Kozlowski LT, Mehta NY, Sweeney CT, et al. Filter ventilation and nicotine content of tobacco in cigarettes from Canada, the United Kingdom, and the United States. *Tob Control* 1998;7:369–375.
61. Kozlowski LT, O'Connor RJ, Giovino GA, et al. Maximum yields might improve public health—if filter vents were banned: a lesson from the history of vented filters. *Tob Control* 2006;15:262–266.
62. Kozlowski LT, O'Connor RJ. Cigarette filter ventilation is a defective design because of misleading taste, bigger puffs, and blocked vents. *Tob Control* 2002;11:140–150.
63. Kozlowski LT, Goldberg ME, Yost BA, et al. Smokers are unaware of the filter vents now on most cigarettes: results of a national survey. *Tob Control* 1996;5:265–270.
64. O'Connor RJ, Caruso RV, Borland R, et al. Relationship of cigarette-related perceptions to cigarette design features: findings from the 2009 ITC U.S. Survey. *Nicotine Tob Res* 2013;15:1943–1947.
65. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. *How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General*. Rockville, MD: Centers for Disease Control and Prevention; 2010.
66. Stratton KR. *Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction*. Washington, DC: Institute of Medicine, National Academy Press; 2001.
67. Foulds J, Ramstrom L, Burke M, et al. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. *Tob Control* 2003;12:349–359.
68. Henningfield JE, Fagerstrom KO. Swedish Match Company, Swedish snus and public health: a harm reduction experiment in progress? *Tob Control* 2001;10:253–257.
69. Pepper JK, Brewer NT. Electronic nicotine delivery system (electronic cigarette) awareness, use, reactions and beliefs: a systematic review. *Tob Control* 2013 [Epub ahead of print].
70. Schaller K, Ruppert L, Kahnert S, et al. *Electronic Cigarettes—An Overview*. Heidelberg: German Cancer Research Center (DKFZ); 2013. <http://www.dkfz.de/en/presse/download/RS-Vol19-E-Cigarettes-EN.pdf>
71. Institute of Medicine. *Scientific Standards for Studies on Modified Risk Tobacco Products*. Washington, DC: National Academies Press; 2012.
72. International Agency for Research on Cancer. *Tobacco Smoke and Involuntary Smoking*. Vol 83. Lyon: International Agency for Research on Cancer, World Health Organization; 2004.
73. International Agency for Research on Cancer. *Smokeless Tobacco and Tobacco-Specific Nitrosamines*. Vol 89. Lyon: International Agency for Research on Cancer, World Health Organization; 2007.
74. Center for Tobacco Products. *Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a) (3) of the Federal Food, Drug, and Cosmetic Act*. Rockville, MD: Department of Health and Human Services; 2012.
75. Fowles J, Dybing E. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. *Tob Control* 2003;12:424–430.
76. Burns DM, Dybing E, Gray N, et al. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization tobacco regulation proposal. *Tob Control* 2008;17:132–141.
77. Straif K, Baan R, Gosse Y, et al. Carcinogenicity of polycyclic aromatic hydrocarbons. *Lancet Oncol* 2005;6:931–932.
78. O'Connor RJ, Hurley PJ. Existing technologies to reduce specific toxicant emissions in cigarette smoke. *Tob Control* 2008;17:i39–i48.
79. Pappas RS. Toxic elements in tobacco and in cigarette smoke: inflammation and sensitization. *Metalloids* 2011;3:1181–1198.
80. Marano KM, Naufal ZS, Kathman SJ, et al. Cadmium exposure and tobacco consumption: biomarkers and risk assessment. *Regul Toxicol Pharmacol* 2012;64:243–252.
81. Stephens WE, Calder A, Newton J. Source and health implications of high toxic metal concentrations in illicit tobacco products. *Environ Sci Technol* 2005;39:479–488.
82. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. *Carcinogenesis* 1988;9:875–884.
83. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. *Chem Res Toxicol* 1998;11:559–603.
84. Hoffmann D, Rivenson A, Hecht SS. The biological significance of tobacco-specific N-nitrosamines: smoking and adenocarcinoma of the lung. *Crit Rev Toxicol* 1996;26:199–211.
85. Nilsson R. The molecular basis for induction of human cancers by tobacco specific nitrosamines. *Regul Toxicol Pharmacol* 2011;60:268–280.
86. Hecht SS, Stepanov I, Hatsukami DK. Major tobacco companies have technology to reduce carcinogen levels but do not apply it to popular smokeless tobacco products. *Tob Control* 2011;20:443.
87. Stepanov I, Knezevich A, Zhang L, et al. Carcinogenic tobacco-specific N-nitrosamines in US cigarettes: three decades of remarkable neglect by the tobacco industry. *Tob Control* 2012;21:44–48.
88. Stanfill SB, Connolly GN, Zhang L, et al. Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines. *Tob Control* 2011;20:e2.
89. Stepanov I, Villalta PW, Knezevich A, et al. Analysis of 23 polycyclic aromatic hydrocarbons in smokeless tobacco by gas chromatography-mass spectrometry. *Chem Res Toxicol* 2010;23:66–73.
90. Stanton MF, Miller E, Wrench C, et al. Experimental induction of epidermoid carcinoma in the lungs of rats by cigarette smoke condensate. *J Natl Cancer Inst* 1972;49:867–877.
91. Hoffmann D, Stepanov I, Hecht SS, et al. *Tobacco Carcinogenesis*. New York: Academic Press; 1978.
92. Deutsch-Wenzel R, Brune H, Grimmer G. Experimental studies in rat lungs on the carcinogenicity and dose-response relationships of eight frequently occurring environmental polycyclic aromatic hydrocarbons. *J Natl Cancer Inst* 1983;71:539–544.
93. Pfeiffer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. *Oncogene* 2002;21:7435–7451.
94. Boysen G, Hecht SS. Analysis of DNA and protein adducts of benzo[a]pyrene in human tissues using structure-specific methods. *Mutat Res* 2003;543:17–30.
95. Phillips DH. Smoking-related DNA and protein adducts in human tissues. *Carcinogenesis* 2002;23:1979–2004.
96. Liu Z, Muehlbauer KR, Schmeiser HH, et al. p53 Mutations in benzo[a]pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. *Cancer Res* 2005;65:2583–2587.
97. Belinsky SA, Foley JF, White CM, et al. Dose-response relationship between O6-methylguanine formation in Clara cells and induction of pulmonary neoplasia in the rat by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. *Cancer Res* 1990;50:3772–3780.
98. Stepanov I, Sebero E, Wang R, et al. Tobacco-specific N-nitrosamine exposures and cancer risk in the Shanghai cohort study: remarkable coherence with rat tumor sites. *Int J Cancer* 2014;134:2278–2283.
99. Yuan JM, Koh WP, Murphy SE, et al. Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. *Cancer Res* 2009;69:2990–2995.
100. Church TR, Anderson SE, Caporaso NE, et al. A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. *Cancer Epidemiol Biomarkers Prev* 2009;18:260–266.
101. Hecht SS, Murphy SE, Stepanov I, et al. Tobacco smoke biomarkers and cancer risk among male smokers in the Shanghai Cohort Study. *Cancer Lett* 2012 [Epub ahead of print].
102. Yuan JM, Butler LM, Gao YT, et al. Urinary metabolites of a polycyclic aromatic hydrocarbon and volatile organic compounds in relation to lung cancer development in lifelong never smokers in the Shanghai Cohort Study. *Carcinogenesis* 2014;35:339–345.
103. Melikian AA, Sun P, Prokopczyk B, et al. Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. *Cancer Lett* 1999;146:127–134.
104. Prokopczyk B, Trushin N, Leszczynska J, et al. Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via alpha-hydroxylation and carbonyl reduction pathways. *Carcinogenesis* 2001;22:107–114.
105. Castela JE, Yuan JM, Skipper PL, et al. Gender- and smoking-related bladder cancer risk. *J Natl Cancer Inst* 2001;93:538–545.
106. Sugimura T. History, present and future, of heterocyclic amines, cooked food mutagens. *Princess Takamatsu Symp* 1995;23:214–231.
107. Turesky RJ. Heterocyclic aromatic amine metabolism, DNA adduct formation, mutagenesis, and carcinogenesis. *Drug Metab Rev* 2002;34:625–650.
108. Ashley DL, O'Connor RJ, Bernert JT, et al. Effect of differing levels of tobacco-specific nitrosamines in cigarette smoke on the levels of biomarkers in smokers. *Cancer Epidemiol Biomarkers Prev* 2010;19:1389–1398.
109. Hatsukami DK, Benowitz NL, Rennard SI, et al. Biomarkers to assess the utility of potential reduced exposure tobacco products. *Nicotine Tob Res* 2008;8:169–191.
110. Carmella SG, Chen M, Han S, et al. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. *Chem Res Toxicol* 2009;22:734–741.
111. Carmella SG, Ming X, Olvera N, et al. High throughput liquid and gas chromatography-tandem mass spectrometry assays for tobacco-specific nitrosamine and polycyclic aromatic hydrocarbon metabolites associated with lung cancer in smokers. *Chem Res Toxicol* 2013;26:1209–1217.
112. Church TR, Anderson KE, Le C, et al. Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers. *Biomarkers* 2010;15:345–352.
113. Hecht SS, Yuan JM, Hatsukami D. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. *Chem Res Toxicol* 2010;23:1001–1008.
114. Hecht SS. Tobacco smoke carcinogens and lung cancer. *J Natl Cancer Inst* 1999;91:1194–1210.
115. Hecht SS. Tobacco carcinogens, their biomarkers, and tobacco-induced cancer. *Nature Rev Cancer* 2003;3:733–744.
116. Hecht SS. Lung carcinogenesis by tobacco smoke. *Int J Cancer* 2012;131:2724–2732.

117. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. *Chem Res Toxicol* 2001;14:611–650.
118. Jalas J, Hecht SS, Murphy SE. Cytochrome P450 2A enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific carcinogen. *Chem Res Toxicol* 2005;18:95–110.
119. Nebert DW, Dalton TP, Okey AB, et al. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. *J Biol Chem* 2004;279:23847–23850.
120. Hang B. Formation and repair of tobacco carcinogen-derived bulky DNA adducts. *J Nucleic Acids* 2010;2010:709521.
121. Burchell B, McGurk K, Brierley CH, et al. *UDP-Glucuronosyltransferases*. Vol 3. New York: Elsevier Science; 1997.
122. Armstrong RN. *Glutathione-S-Transferases*. Vol 3. New York: Elsevier Science; 1997.
123. Vineis P, Veglia F, Benhamou S, et al. CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. *Int J Cancer* 2003;104:650–657.
124. Carlsten C, Sagoo GS, Frodsham AJ, et al. Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and meta-analysis. *Am J Epidemiol* 2008;167:759–774.
125. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. *Cancer* 2001;92:1525–1530.
126. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* 2008;455:1069–1075.
127. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. *Nature* 2001;410:1111–1116.
128. Sekido Y, Fong KW, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. *Biochim Biophys Acta* 1998;1378:F21–F59.
129. Bode AM, Dong A. Signal transduction pathways in cancer development and as targets for cancer prevention. *Prog Nucleic Acid Res Mol Biol* 2005;79:237–297.
130. Schuller HM. Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. *Nat Rev Cancer* 2002;2:455–463.
131. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. *Nat Med* 2001;7:833–839.
132. West KA, Brognard J, Clark AS, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. *J Clin Invest* 2003;111:81–90.
133. Moraitis D, Du B, De Lorenzo MS, et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. *Cancer Res* 2005;65:664–670.